Merck & Co is working a major US hospital provider on a new software system that could help tackle the threat from healthcare-associated C. diff infections.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh